---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-26-000013"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:24:47.423770+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Altimmune ends FY2025 with $274M cash; FDA breakthrough for MASH; Phase 3 planned 2026

## Summary
- Cash, cash equivalents and short-term investments: $274M at Dec 31, 2025; ~$340M after $75M offering and $8M ATM in Jan 2026.
- FY2025 net loss $88.1M ($1.00/share); Q4 net loss $27.4M ($0.27/share).
- Pemvidutide granted FDA Breakthrough Therapy Designation for MASH; Phase 3 trial planned in 2026.
- Topline data from RECLAIM Phase 2 trial in alcohol use disorder expected Q3 2026.
- Jerry Durso appointed CEO; previously CEO of Intercept Pharmaceuticals.

## SEC filing metadata
- accession: 0001326190-26-000013
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/0001326190-26-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/alt-20260305x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-26-000013
- JSON: https://secwatch.observer/filing/0001326190-26-000013.json
- Plain text: https://secwatch.observer/filing/0001326190-26-000013.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: On March 5, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fourth quarter and full year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/0001326190-26-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.